Université De Sherbrooke

Eli Lilly and Company

Societe De Commercialisation Des Produits De La Recherche Appliquee Socpra Sciences Sante Et Humaines S.e.c.

Societe De Commercialisation Des Produits De La Recheche Appliquee-socpra-science Sante Et Humaines S.e.c.

Socpra Sciences Sante Et Humaines S.e.c.

Fernand Gobeil

Witold A Neugebauer

Domenico Regoli

David Fortin

Brigitte Guerin

Pierre Sirois

Jean-Patrice Baillargeon

Martin Lepage

Domenico Recoli

Gerard E Plante

Adriana Zucollo

Orlando L Catanzaro

Jean-luc Ardilouze

Julie Menard

Bichov Gabra

Robert Sabbagh

Maude Gagnon-auger

Pascal Brassard

The present disclosure relates to compositions and combinations comprising one or more insulin(s) and one or more vasoactive agent(s), and use thereof for increasing subcutaneous insulin absorption and/or treating diabetes and/or treating or preventing hyperglycemia or complications in a patient in need thereof.

Pharmaceutical preparation for improving absorption and postprandial hypoglycemic action of insulin

It is provided new chemical entities allowing simultaneous diagnosis and treatment of cancers. More specifically, it is provided a theranostic compound consisting of a stabilized peptide ligand (agonists and antagonists) for the kinin B1 receptors (B1R) conjugated to specific radionuclides (e.g.Cu) suitable for dual imaging/radiotherapy applications.

Kinin-based theranostic probes for solid cancers and uses thereof

The present invention provides for novel kinin B1 receptors peptide agonists of formula (I) having very good to excellent affinities and selectivity for the Breceptor, in vitro and in vivo increased resistance to enzymatic degradation, superior pharmacokinetic properties to those of naturally occurring agents, capacity to significantly enhance delivery of chemotherapeutic substances across the blood brain barrier and within peripheral tissues for the treatment of tumors, capacity to protect and restore kidney, heart, brain and other organ functions, when given alone or in combination with other therapies in the treatment of hypertension, diabetes and other cardiovascular diseases particularly, but not limited to, atherosclerosis and arteriosclerosis. Formula (I): aa-aa-aa-aa-aa-aa-aa-aa-Ser-Pro-D-Phe-X.

[object Object]

The present invention provides for a novel peptidic antagonist for the bradykinin B1 (BKB) receptor having very good to excellent affinities and selectivity for the BKBreceptor, in vitro and in vivo increase resistance to enzymatic degradation, superior pharmacokinetic properties, capability to significantly reduce microvascular leakage observed alongside diabetic-induced increase in vascular permeability, capability to significantly reduced the state of hyperalgesia alongside diabetes, capability to significantly reduce the infiltration of pro-inflammatory cells and general state of inflammation alongside allergic asthma.

Selective bradykinin (BK) B1 peptidic receptor antagonists and uses thereof

The present invention relates to novel antagonists to a B-bradykinin (B-BK) receptor which have a good affinity and selectivity therefor, some of which being at least partially resistant to enzymatic degradation. The synthesis of the Breceptors is induced during inflammation. Symptoms associated with inflammation (elevated hydrostatic pressure and plasma leakage or extravasation) have been observed in diabetic animal models (streptozotocin-induced diabetes (STZ)) as well as in spontaneously hypertensive rats (SHR). The present inventors confirm the presence of B-BK receptors in these two models. B-BK antagonists abolished the vasocontraction induced by B-BK in SHR and STZ, and reduced the glycemia of diabetic animals to normal levels. The present B-antagonists are useful for treating any condition wherein B-receptor is expressed, particularly during inflammation, and more particularly wherein B-receptor expression results in diabetic vasculopathy, other diabetic symptoms associated with an insulitis and a post-capillary resistance building as a consequence of the presence of a B-receptor.

Growing community of inventors

Sherbrooke, Canada

Fernand Gobeil